Results 131 to 140 of about 1,587,143 (318)

Atrial cardiomyopathy: From healthy atria to atrial failure. A clinical consensus statement of the Heart Failure Association of the ESC

open access: yesEuropean Journal of Heart Failure, EarlyView.
The diagnosis of atrial cardiomyopathy (AtCM) requires electrical atrial dysfunction, with evidence of either mechanical atrial dysfunction, atrial enlargement, or excessive atrial fibrosis. The diagnostic cut‐points presented are for standard electrocardiogram and echocardiogram studies (see Figure 1 for further detail).
Jerremy Weerts   +26 more
wiley   +1 more source

Assessment of Sonoelastography as Diagnosis Tool of Inflammatory Myopathies [PDF]

open access: yesApplied Medical Informatics, 2010
Background: Inflammatory myopathies represent a special group of pathology. Establishing the correct diagnosis in the early phase and a better follow-up are the main objective for improving the life quality of these patients.
Carolina BOTAR-JID   +6 more
doaj  

Why do patients with myositis die? A retrospective analysis of a single-centre cohort [PDF]

open access: yes, 2016
OBJECTIVES: Causes of death in inflammatory myopathies have rarely been studied. We have assessed a cohort of myositis patients followed in a single centre over a 37-year period, reviewing the mortality rate, causes of death and predictors of poor ...
Cogollo, E, Isenberg, DA, Silva, MA
core  

Application of Agents Against Interferon-Gamma-Dependent Chemokines in Immunotherapy [PDF]

open access: yes, 2015
The CXC chemokine receptor (CXCR) 3 and its chemokines (CXCL9, CXCL10, CXCL11) are involved in the pathogenesis of autoimmune disesases. Under the influence of interferon (IFN) γ, the IFNγ-inducible chemokines are secreted by lymphocytes, and by ...
Antonelli, Alessandro   +4 more
core   +1 more source

Impact of genotype–phenotype associations on prognosis in dilated cardiomyopathy

open access: yesEuropean Journal of Heart Failure, EarlyView.
Prediction of clinical outcomes in genetic dilated cardiomyopathy (DCM). LVEF, left ventricular ejection fraction. Aims Dilated cardiomyopathy (DCM) has a monogenic aetiology in up to 40% of patients. Understanding the spectrum of genotype–phenotype associations in DCM is crucial for risk stratification and personalized treatment.
Sophie L.V.M. Stroeks   +27 more
wiley   +1 more source

Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. [PDF]

open access: yes, 2008
Distinct interrelationships between inflammation and beta-amyloid-associated degeneration, the two major hallmarks of the skeletal muscle pathology in sporadic inclusion body myositis (sIBM), have remained elusive.
Barthel, Konstanze   +5 more
core   +1 more source

Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database. [PDF]

open access: yes, 2017
Racial differences exist in the severity of systemic sclerosis (SSc). To enhance our knowledge about SSc in African Americans, we established a comprehensive clinical database from the largest multicenter cohort of African American SSc patients assembled
Boin, Francesco   +28 more
core   +1 more source

Inherited metabolic epilepsies–established diseases, new approaches

open access: yesEpilepsia Open, EarlyView.
Abstract Inherited metabolic epilepsies (IMEs) represent the inherited metabolic disorders (IMDs) in which epilepsy is a prevailing component, often determining other neurodevelopmental outcomes associated with the disorder. The different metabolic pathways affected by individual IMEs are the basis of their rarity and heterogeneity.
Itay Tokatly Latzer, Phillip L. Pearl
wiley   +1 more source

Anti-nuclear matrix protein 2 antibody-positive idiopathic inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash [PDF]

open access: green, 2021
Yuki Ichimura   +20 more
openalex   +1 more source

Neurological complications of immune checkpoint inhibitors: what happens when you \u27take the brakes off\u27 the immune system. [PDF]

open access: yes, 2018
Patients with advanced malignancies treated with immune checkpoint inhibitors are at increased risk for developing immune-related neurological complications.
Dalakas, Marinos
core   +1 more source

Home - About - Disclaimer - Privacy